MANNKIND CORP
Close on Oct 19, 2026
- Market cap
- $955.40M
- P/E (TTM)
- –
- Dividend yield
- –
About Mannkind
Pharmaceutical Preparations, SIC 2834
The company develops, manufactures, and commercializes therapeutic products and drug delivery systems for patient care. Its product portfolio includes Afrezza, Tyvaso DPI, V-Go, and Furoscix, alongside an on-body infusor technology and inhaled insulin formulations. In addition to commercial product sales, the enterprise provides contract manufacturing, development, and commercial supply services, and licenses its proprietary technologies. Its operations serve pharmaceutical and healthcare partners, with key collaborations and agreements involving United Therapeutics Corporation, Cipla, scPharmaceuticals, and Amphastar.
The entity conducts operations across several locations, maintaining business activities and leased properties in Connecticut and Minnesota, as well as facilities in Marlborough and on Russell Ranch Road. Internationally, commercial arrangements and distribution licensing relationships extend to India. The enterprise operates across these regional sites to support research, commercial manufacturing, and collaborative pharmaceutical distribution.
Summary of the business section of Mannkind's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MANNKIND CORP
- Founded
- 1991
- Headquarters
- Danbury, CT
- Address
- 1 Casper Street 06810
- Phone
- (818) 661-5000
- Website
- mannkindcorp.com
- Employees
- 241, Dec 31, 2020
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Los Angeles, California
Stock & identifiers
- Ticker
- MNKD
- Exchange
- Nasdaq
- IPO date
- Jul 28, 2004
- Shares outstanding
- 322M, Jul 24, 2026
- Public float
- $1.13B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-5 reverse, Mar 3, 2017; 1-for-5 reverse, Mar 1, 2017
- SEC CIK
- 899460
- CUSIP
- 56400P706
- ISIN
- US56400P7069
- LEI
- 213800GFBCNY1ZFST722
- EIN
- 13-3607736
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael Castagna | Chief Executive Officer, Director | 2,494,183 |
| David Thomson | EVP Genl Counsel & Secretary | 797,554 |
| Christopher B. Prentiss | Chief Financial Officer | 318,668 |
| Sanjay R. Singh | EVP Technical Operations | 478,966 |
| Stuart A. Tross | Chief People & Workpl Officer | 1,123,950 |
| Dominic Marasco | Pres, Endocrine Business Unit | 343,398 |
| Ajay Ahuja | Chief Medical Officer | 318,200 |
| Burkhard Blank | EVP Chief Medical Officer | 460,791 |
| Lauren M. Sabella | EVP Operations | 349,841 |
| Steven B. Binder | Director | 713,258 |
| James Samuel Shannon | Director | 36,458 |
| Christine Mundkur | Director | 27,675 |
| Jennifer Grancio | Director | 110,701 |
| Sabrina Kay | Director | 107,033 |
| Michael A. Friedman | Director | 86,700 |
| Ronald J. Consiglio | Director | 132,342 |
| Anthony C. Hooper | Director | 236,153 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Michael E. Castagna | $9.30M | $752.39K | $3.99M | $181 | $125 |
| FY2024 Michael E. Castagna | $9.49M | $22.84M | $2.89M | $205 | $93 |
| FY2023 Michael E. Castagna | $7.07M | $96.76K | $2.20M | $116 | $94 |
| FY2022 Michael E. Castagna | $3.91M | $9.65M | $1.48M | $168 | $90 |
| FY2021 Michael E. Castagna | $4.03M | $7.32M | $1.73M | $140 | $100 |
| FY2020 Michael E. Castagna | $3.56M | $7.42M | $1.61M | $243 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2020, we had 241 total employees, of which 240 were full-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 9, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 8, 2025 | Tender offer | Third-party tender offer for the company's shares |
| Dec 7, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 23, 2017 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 7, 2016 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 22, 2016 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 1, 2016 | Late filing | Notification of late filing |
| Jul 28, 2004 | IPO | Initial public offering priced (424B4 prospectus) |